Evaluation the Association of Microbiome Between Respiratory Tract Samples and Stool Samples in Pneumonic Patients Accompanied by Respiratory Failure
Department of Critical Care Medicine, Taichung Veterans General Hospital
A prospective observational study. Enrolled participants admitted to ICU due to pneumonia and respiratory failure need mechanical ventilator support. Investigators collected the residual specimens, such as sputum from endotrachea aspiration, bronchoalveolar lavage fluid in those participants as the usual care in the ICU. Those residual samples were sent to extract RNA and sequence by using high-throughput sequencing (next-generation sequencing) method.
Investigators will compared the microbiome feature between lower respiratory tract and stool specimens in those participants diagnosed as pneumonia with respiratory failure.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults aged than 40 years old
- Diagnosed as pneumonia
- Respiratory failure with mechanical ventilator support
Exclusion Criteria:
- Less than 40 years old
- Has been treated with antibiotics more than 7 days within two weeks before enrolling into study
- Suspected or active pulmonary tuberculosis infection
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Pneumonia patient with respiratory failure
Sputum and stool sampling day 1, 3 and 7 after enrolling into study
|
We will check the microbiome in lower respiratory samples (sputum and bronchoalveolar lavage fluid) and stool by using 16S RNA sequencing
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The dynamics of the airway bacterial microbiome in the lower respiratory tract specimens in the setting of pneumonia accompanied by respiratory failure at the onset of, and day 3 and day 7 (or before extubation)
Time Frame: Compared the dynamic change of mirobiome at the baseline (onset of respiratory failure within 48 hours)m day 3 and day 7
|
Uses high-throughput sequencing (next-generation sequencing) to sequence the 16S rRNA sequence of bacteria in residual samples
|
Compared the dynamic change of mirobiome at the baseline (onset of respiratory failure within 48 hours)m day 3 and day 7
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The dynamics of the gut bacterial microbiome in the stool specimens in the setting of pneumonia accompanied by respiratory failure at the onset of, and day 3 and day 7 (or before extubation)
Time Frame: Compared the dynamic change of mirobiome at the baseline (onset of respiratory failure within 48 hours)m day 3 and day 7
|
uses high-throughput sequencing (next-generation sequencing) to sequence the 16S
|
Compared the dynamic change of mirobiome at the baseline (onset of respiratory failure within 48 hours)m day 3 and day 7
|
|
The association of the microbiome between lower respiratory tracts and stool specimens in pneumonic patient with respiratory failure
Time Frame: Compared the association of mirobiome at the baseline (onset of respiratory failure within 48 hours)m day 3 and day 7
|
Uses high-throughput sequencing (next-generation sequencing) to sequence the 16S
|
Compared the association of mirobiome at the baseline (onset of respiratory failure within 48 hours)m day 3 and day 7
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Pin-Kuei Fu, MD, PhD, Taichung Veterans General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Respiratory Insufficiency
- Pneumonia
- Pneumonia, Bacterial
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Dimercaprol
Other Study ID Numbers
Other Study ID Numbers
- IGA-10601
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Failure
-
NCT04183660RecruitingRespiratory Failure | Cardiac Failure | Cardio-Respiratory Failure | Imminent Cardiorespiratory or Respiratory Failure
-
NCT07334457RecruitingRespiratory Failure | Cardiac Failure
-
NCT02107183CompletedWeaning Failure | Acute Respiratory Failure
-
NCT03872167CompletedHypercapnic Respiratory Failure | Hypoxemic Respiratory Failure
-
NCT04079829UnknownShock | Shock, Septic | Respiratory Failure | Respiratory Distress Syndrome | Shock, Cardiogenic | Acute Cardiac Failure | Acute Respiratory Failure | Acute Kidney Failure | Multi Organ Failure | Respiratory Arrest
-
NCT00977002UnknownExtubation Failure | Acute Respiratory Failure Post Extubation
-
NCT06694870CompletedHypercapnic Respiratory Failure | Type 2 Respiratory Failure
-
NCT06007495RecruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory Failure
-
NCT06204276CompletedAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory Failure
-
NCT03082105CompletedHypercapnic Respiratory Failure | Hypoxic Respiratory Failure | Avalanche Burial | Snow Physical Properties
Clinical Trials on 16s RNA sequence of sputum, bronchoalveolar lavage fluid (options), stool
-
NCT05007340RecruitingRheumatic Diseases | Systemic Lupus Erythematosus | Systemic Sclerosis | Interstitial Lung Disease | Usual Interstitial Pneumonia | Nonspecific Interstitial Pneumonia | Rheumatic Arthritis | Systemic Autoimmune Disease | Autoimmune Myositis
-
NCT03557749TerminatedCytokine Release Syndrome | Immune and Microbial Reconstitution | Systemic Viral Infection | Acute-graft-versus-host Disease | Chronic Graft-versus-host-disease | Recurrent Malignancy | Allogenic Related Donors | Cell Therapy/Immunotherapy Patients